CHILDHOOD ABSENCE EPILEPSY: RX, PK-PD-PHARMACOGENETICS

儿童失神癫痫：RX、PK-PD-药物遗传学

• 批准号: 8167077
• 负责人: RAMAN SANKAR
• 金额: $ 0.73万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167077
• 关键词: Absence Epilepsy; Adverse effects; Antiepileptic Agents; Attention; Behavior; Child; Childhood; Clinical Trials Design; Cognition; Computer Retrieval of Information on Scientific Projects Database; Ethosuximide; Failure; Freedom; Funding; Grant; Institution; Pharmacogenetics; Quality of life; Research; Research Personnel; Resources; Risk; Seizures; Source; United States National Institutes of Health; Valproic Acid; lamotrigine; time use

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Specific Aim 1a: To determine whether ethosuximide (ETX), lamotrigine (LTG) or valproic acid (VPA) is the most effective initial monotherapy for pediatric subjects with childhood absence epilepsy (CAE), defined as the antiepileptic drug (AED) with the greatest likelihood of seizure control and lowest risk of treatment limiting side effects over time, using a freedom from failure trial design. Specific Aim 1b: To define and contrast the effects of ETX, LTG, and VPA monotherapy on cognition (especially attention), behavior and quality of life in children with CAE.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 具体目标 1a：采用无失败试验设计，确定乙舒酰亚胺 (ETX)、拉莫三嗪 (LTG) 或丙戊酸 (VPA) 是否是儿童失神癫痫 (CAE) 儿科受试者最有效的初始单一疗法，CAE 被定义为最有可能控制癫痫发作且随时间推移限制副作用的治疗风险最低的抗癫痫药物 (AED)。 具体目标 1b：定义并对比 ETX、LTG 和 VPA 单一疗法对 CAE 儿童认知（尤其是注意力）、行为和生活质量的影响。